{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:37:57Z","timestamp":1794490677431,"version":"4.9.1"},"reference-count":65,"publisher":"BMJ","issue":"7400","license":[{"start":{"date-parts":[[2003,5,29]],"date-time":"2003-05-29T00:00:00Z","timestamp":1054166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2003,4,15]]},"published-print":{"date-parts":[[2003,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    To investigate whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    Medline (January 1966 to December 2002) and Embase (January 1980 to December 2002) searches were supplemented with material identified in the references and in the authors' personal files. Data were independently abstracted by three of the authors and disagreements were resolved by consensus.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    30 studies were included. Research funded by drug companies was less likely to be published than research funded by other sources. Studies sponsored by pharmaceutical companies were more likely to have outcomes favouring the sponsor than were studies with other sponsors (odds ratio 4.05; 95% confidence interval 2.98 to 5.51; 18 comparisons). None of the 13 studies that analysed methods reported that studies funded by industry was of poorer quality.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    Systematic bias favours products which are made by the company funding the research. Explanations include the selection of an inappropriate comparator to the product being investigated and publication bias.\n                  <\/jats:p>","DOI":"10.1136\/bmj.326.7400.1167","type":"journal-article","created":{"date-parts":[[2003,5,29]],"date-time":"2003-05-29T18:21:56Z","timestamp":1054232516000},"page":"1167-1170","source":"Crossref","is-referenced-by-count":1554,"title":["Pharmaceutical industry sponsorship and research outcome and quality: systematic review"],"prefix":"10.1136","volume":"326","author":[{"given":"Joel","family":"Lexchin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A","family":"Bero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Djulbegovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2003,5,29]]},"reference":[{"key":"2025122211232469000_326.7400.1167.1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92245-W"},{"key":"2025122211232469000_326.7400.1167.2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/art.1780341015","article-title":"Secular changes in published clinical trials of second-line agents in rheumatoid arthritis.","volume":"34","author":"Anderson","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2025122211232469000_326.7400.1167.3","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1161\/01.STR.30.10.1995","article-title":"Reports of randomized trials in acute stroke, 1955 to 1995: what proportions were commercially sponsored?","volume":"30","author":"Dorman","year":"1999","journal-title":"Stroke"},{"key":"2025122211232469000_326.7400.1167.4","unstructured":"Pharmaceutical Research and Manufacturers of America . 2001 industry profile. Washington, DC: PhRMA, 2003. http:\/\/www.phrma.org\/publications\/publications\/profile02\/index.cfm (accessed 6 May 2003)."},{"key":"2025122211232469000_326.7400.1167.5","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200018010-00006"},{"key":"2025122211232469000_326.7400.1167.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.16.2116"},{"key":"2025122211232469000_326.7400.1167.7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/S0266462300009582","article-title":"Influences on the quality of published drug studies.","volume":"12","author":"Bero","year":"1996","journal-title":"Int J Tech Assess Health Care"},{"key":"2025122211232469000_326.7400.1167.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.4.454"},{"key":"2025122211232469000_326.7400.1167.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.11.1054"},{"key":"2025122211232469000_326.7400.1167.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.11.1083"},{"key":"2025122211232469000_326.7400.1167.11","unstructured":"Hennekens CH Buring JE . Epidemiology in medicine. Boston: Little, Brown, and Company, 1987."},{"key":"2025122211232469000_326.7400.1167.12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1998.00201.x"},{"key":"2025122211232469000_326.7400.1167.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.6.414"},{"key":"2025122211232469000_326.7400.1167.14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-124-5-199603010-00004","article-title":"The quality of drug studies published in symposium proceedings.","volume":"124","author":"Cho","year":"1996","journal-title":"Ann Intern Med"},{"key":"2025122211232469000_326.7400.1167.15","unstructured":"Clifford TJ Moher D Barrowman N . Funding source, trial outcome and reporting quality: are they related? Results of a pilot study."},{"key":"2025122211232469000_326.7400.1167.16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02602327","article-title":"Source of funding and outcome of clinical trials.","volume":"1","author":"Davidson","year":"1986","journal-title":"J Gen Intern Med"},{"key":"2025122211232469000_326.7400.1167.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480030052036"},{"key":"2025122211232469000_326.7400.1167.18","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/S0140-6736(05)75755-X","article-title":"Funding clinical research.","volume":"353","author":"Dieppe","year":"1999","journal-title":"Lancet"},{"issue":"suppl 1","key":"2025122211232469000_326.7400.1167.19","first-page":"399A","article-title":"Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoietin (EPO).","volume":"94","author":"Djulbegovic","year":"1999","journal-title":"Blood"},{"key":"2025122211232469000_326.7400.1167.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02605-2"},{"key":"2025122211232469000_326.7400.1167.21","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90201-Y"},{"key":"2025122211232469000_326.7400.1167.22","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.177.4.292"},{"key":"2025122211232469000_326.7400.1167.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.15.1453"},{"key":"2025122211232469000_326.7400.1167.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.4.281"},{"key":"2025122211232469000_326.7400.1167.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7234.537"},{"key":"2025122211232469000_326.7400.1167.26","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.156.10.1034"},{"key":"2025122211232469000_326.7400.1167.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7305.131"},{"key":"2025122211232469000_326.7400.1167.28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300510"},{"key":"2025122211232469000_326.7400.1167.29","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008309817708"},{"key":"2025122211232469000_326.7400.1167.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.24.2287"},{"key":"2025122211232469000_326.7400.1167.31","first-page":"268","article-title":"Empiric evidence of publication bias affecting acute stroke clinical trials.","volume":"30","author":"Liebeskind","year":"1999","journal-title":"Stroke"},{"key":"2025122211232469000_326.7400.1167.32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4088\/JCP.v60n0210a","article-title":"Manufacturer support and outcome.","volume":"60","author":"Mandelkern","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"2025122211232469000_326.7400.1167.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304223281612"},{"key":"2025122211232469000_326.7400.1167.34","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.19.2.92"},{"key":"2025122211232469000_326.7400.1167.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520020034009"},{"key":"2025122211232469000_326.7400.1167.36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00019053-199711030-00010","article-title":"Publication bias in health economic studies.","volume":"11","author":"Sacrist\u00e1n","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"2025122211232469000_326.7400.1167.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.640"},{"key":"2025122211232469000_326.7400.1167.38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(02)07506-2","article-title":"Sponsorship, authorship, and accountability.","volume":"359","author":"Thomas","year":"2002","journal-title":"Lancet"},{"key":"2025122211232469000_326.7400.1167.39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7231.381"},{"key":"2025122211232469000_326.7400.1167.40","first-page":"465","article-title":"Sponsored drug trials show more-favourable outcomes.","volume":"318","author":"Wahlbeck","year":"1999","journal-title":"BMJ"},{"key":"2025122211232469000_326.7400.1167.41","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/18.6.565"},{"issue":"suppl II","key":"2025122211232469000_326.7400.1167.42","first-page":"390S","article-title":"Impact of pharmaceutical industry funding of clinical research: results of a survey of antianginal trials.","volume":"70","author":"Massie","year":"1984","journal-title":"Circulation"},{"key":"2025122211232469000_326.7400.1167.43","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420020059007"},{"key":"2025122211232469000_326.7400.1167.44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11912-001-0024-5","article-title":"Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research.","volume":"3","author":"Djulbegovic","year":"2001","journal-title":"Cur Oncol Rep"},{"issue":"12","key":"2025122211232469000_326.7400.1167.45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3120","article-title":"Assessing the quality of reports of randomized trials: implications for the conduct of meta-analyses.","volume":"3","author":"Moher","year":"1999","journal-title":"Health Technol Assess"},{"key":"2025122211232469000_326.7400.1167.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)01085-X"},{"key":"2025122211232469000_326.7400.1167.47","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90017-2"},{"key":"2025122211232469000_326.7400.1167.48","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-200209000-00002"},{"key":"2025122211232469000_326.7400.1167.49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.18.1752"},{"key":"2025122211232469000_326.7400.1167.50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540390068038"},{"key":"2025122211232469000_326.7400.1167.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)00072-0"},{"key":"2025122211232469000_326.7400.1167.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03166-4"},{"key":"2025122211232469000_326.7400.1167.53","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM199210153271606","article-title":"The publication of sponsored symposiums in medical journals.","volume":"327","author":"Bero","year":"1992","journal-title":"N Engl J Med"},{"key":"2025122211232469000_326.7400.1167.54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.24.2287"},{"key":"2025122211232469000_326.7400.1167.55","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1136\/bmj.318.7200.1762a","article-title":"Sponsored trials do not necessarily give more-favourable results.","volume":"318","author":"Matthews","year":"1999","journal-title":"BMJ"},{"key":"2025122211232469000_326.7400.1167.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02351-5"},{"key":"2025122211232469000_326.7400.1167.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90153-1"},{"key":"2025122211232469000_326.7400.1167.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMed20010093"},{"key":"2025122211232469000_326.7400.1167.59","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-8-200104170-00012"},{"key":"2025122211232469000_326.7400.1167.60","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.15.1987"},{"key":"2025122211232469000_326.7400.1167.61","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)00328-1"},{"key":"2025122211232469000_326.7400.1167.62","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.1986.4.10.1529","article-title":"Publication bias: the case for an international registry of clinical trials.","volume":"4","author":"Simes","year":"1986","journal-title":"J Clin Oncol"},{"key":"2025122211232469000_326.7400.1167.63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(88)90002-5","article-title":"Toward prospective registration of clinical trials.","volume":"9","author":"Meinert","year":"1988","journal-title":"Control Clin Trials"},{"key":"2025122211232469000_326.7400.1167.64","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03440100121018"},{"key":"2025122211232469000_326.7400.1167.65","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/bmj.319.7214.865","article-title":"The time to register randomized trials.","volume":"319","author":"Horton","year":"1999","journal-title":"BMJ"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.326.7400.1167","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.326.7400.1167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T19:23:36Z","timestamp":1766431416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.326.7400.1167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,29]]},"references-count":65,"journal-issue":{"issue":"7400","published-online":{"date-parts":[[2003,5,29]]},"published-print":{"date-parts":[[2003,5,31]]}},"alternative-id":["10.1136\/bmj.326.7400.1167"],"URL":"https:\/\/doi.org\/10.1136\/bmj.326.7400.1167","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,29]]}}}